0001104659-24-070108.txt : 20240610
0001104659-24-070108.hdr.sgml : 20240610
20240610203011
ACCESSION NUMBER: 0001104659-24-070108
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240610
DATE AS OF CHANGE: 20240610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Xynos Konstantinos
CENTRAL INDEX KEY: 0001956241
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 241034431
MAIL ADDRESS:
STREET 1: C/O REPLIMUNE GROUP, INC.
STREET 2: 500 UNICORN PARK DRIVE
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
tm2416882-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-06-07
0
0001737953
Replimune Group, Inc.
REPL
0001956241
Xynos Konstantinos
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK DRIVE, SUITE 303
WOBURN
MA
01801
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-06-07
4
S
0
15881
7.50
D
117131
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof.
/s/ Shawn Glidden, attorney-in-fact
2024-06-10